---
title: "Edding Genor Expands Global Rights to Key siRNA Drug as It Streamlines Nanopeptide Collaboration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277649007.md"
description: "Edding Genor Group Holdings has expanded its global rights to a key siRNA drug targeting ANGPTL3, restructuring its collaboration with Nanopeptide. The company now holds worldwide patent rights and jointly owns the GalNAc platform technology. This strategic move enhances the importance of ANGPTL3 in its pipeline, particularly with the lead candidate EDP167 entering phase II trials. Concurrently, Edding Genor has terminated cooperation on two pre-clinical siRNA assets due to market competition. The latest analyst rating for Genor Biopharma Holdings (HK:6998) is a Hold with a price target of HK$2.50."
datetime: "2026-03-03T15:10:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277649007.md)
  - [en](https://longbridge.com/en/news/277649007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277649007.md)
---

# Edding Genor Expands Global Rights to Key siRNA Drug as It Streamlines Nanopeptide Collaboration

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Genor Biopharma Holdings Limited ( (HK:6998) ) has issued an update.

Edding Genor Group Holdings has restructured its collaboration with Nanopeptide, expanding the territorial scope of its key siRNA asset targeting ANGPTL3 from selected regions to worldwide, and securing global patent rights to the molecule while jointly owning the GalNAc platform technology. The move strengthens the strategic importance of ANGPTL3 within the company’s pipeline, where lead candidate EDP167 has begun phase II trials, and is expected to enhance long-term shareholder value.

At the same time, Edding Genor and Nanopeptide have terminated cooperation on two other pre-clinical siRNA assets, a decision the company attributes to a competitive market landscape and the early development stage of those programs. Management emphasized that discontinuing these projects should not materially affect the group’s business, financial condition or operations, suggesting a focused capital allocation strategy around its most promising RNA therapy asset.

The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.

**More about Genor Biopharma Holdings Limited**

Edding Genor Group Holdings Limited is a biopharmaceutical company focused on the development, manufacturing and commercialisation of innovative drug candidates, including RNA-based therapies such as small interfering RNA (siRNA) assets. The group targets global markets for cardiovascular and metabolic disease treatments, with a growing pipeline led by its ANGPTL3-targeting candidate EDP167.

**Average Trading Volume:** 1,338,171

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$5.26B

For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.

### Related Stocks

- [06998.HK](https://longbridge.com/en/quote/06998.HK.md)

## Related News & Research

- [Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing](https://longbridge.com/en/news/287870663.md)
- [Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease](https://longbridge.com/en/news/287850086.md)
- [12:00 ETEclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution](https://longbridge.com/en/news/288302490.md)
- [22:31 ETAddiVance Offers Families a Drug-Free Option for Daily Focus, Attention, and Cognitive Support](https://longbridge.com/en/news/288353835.md)
- [Akeso lung cancer drug trial raises hopes in US$20b market](https://longbridge.com/en/news/288280716.md)